TG
CORT icon

TCW Group’s Corcept Therapeutics CORT Stock Holding History

TCW Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-37,048
Closed -$103K – 729
2014
Q2 		$103K Hold
37,048
– – ﹤0.01% 739
2014
Q1 		$162K Sell
37,048
-35,900
-49% -$125K ﹤0.01% 748
2013
Q4 		$234K Hold
72,948
– – ﹤0.01% 744
2013
Q3 		$116K Hold
72,948
– – ﹤0.01% 739
2013
Q2 		$126K Buy
+72,948
New +$131K ﹤0.01% 709

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
CCA
Catalyst Capital Advisors Huntington, New York $6.03B AUM 24.5% 1-Year Est. Return

TCW Group's CORT Position: Q3 2014 in Review

TCW Group sold out of Corcept Therapeutics (CORT) in Q3 2014, closing a stake of 37,048 shares — an estimated $103K sold.

TCW Group first reported a position in CORT in Q2 2013 and held it in 5 quarters. The position peaked at $234K in Q4 2013. 55 funds tracked by Wall St. Rank hold CORT as of Q3 2014.

  • TCW Group reported no remaining Corcept Therapeutics position as of Q3 2014 after selling out during the quarter.
  • TCW Group sold 37,048 Corcept Therapeutics shares in Q3 2014, an estimated $103K.
  • TCW Group first reported a position in Corcept Therapeutics in Q2 2013 and held it in 5 quarters.
  • TCW Group's Corcept Therapeutics position peaked at $234K in Q4 2013.
  • 55 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2014.

Based on TCW Group's 13F filing for Q3 2014, filed 14 Nov 2014.